Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
February 20, 2024 at 06:20 am EST
Share
Nexien BioPharma, Inc. reported earnings results for the second quarter and six months ended December 31, 2023. For the second quarter, the company reported net loss was USD 0.024518 million compared to USD 0.093592 million a year ago.
For the six months, net loss was USD 0.099436 million compared to USD 0.188466 million a year ago.
Nexien BioPharma, Inc. is engaged in pre-clinical and drug development activities for certain pharmaceutical formulations that include cannabinoids. The Company is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The Company's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.
NEXIEN BIOPHARMA, INC. 
